Abstract: The invention provides a protein that is a tumor marker protein. This protein can be used to prepare antibodies that bind to the tumor marker protein. These antibodies can be used to reduce, or eliminate metastasis by cancer cells that produce the tumor marker protein. In addition, the invention provides methods that can be used to diagnose cancer, and metastasis by cancer cells.
Type:
Grant
Filed:
February 18, 2004
Date of Patent:
September 15, 2009
Assignee:
The Scripps Research Institute
Inventors:
James P. Quigley, John D. Hooper, Jacqueline E. Testa
Abstract: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and aniino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.
Type:
Grant
Filed:
July 10, 2002
Date of Patent:
September 8, 2009
Assignee:
Biotechnol S.A.
Inventors:
Giuseppe D'Alessio, Renata Piccoli, Claudia De Lorenzo, Donald Balfour Palmer, Mary Alice Ritter
Abstract: The present invention is directed to a treatment for cancer. Compositions and methods of treating cancer are included in the scope of the present invention. The compositions of the present invention include a composition prepared from tumor cells or tumor cell extracts. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a composition comprising tumor cells and/or tumor cell extracts.
Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.
Type:
Grant
Filed:
December 17, 2002
Date of Patent:
September 1, 2009
Assignee:
Zymogenetics, Inc.
Inventors:
Yasmin A. Chandrasekher, Patricia A. McKernan
Abstract: The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.
Type:
Grant
Filed:
April 30, 2003
Date of Patent:
August 25, 2009
Assignee:
Wake Forest University Health Sciences
Inventors:
Jianfeng Xu, Deborah Meyers, Sigun Zheng, Patrick C. Walsh, William B. Isaacs, Eugene Bleecker, David Herrington
Abstract: According to the present invention it is now disclosed that exposure of antigen presenting cells, particularly dendritic cells, to peptides or peptide analogs derived from heat shock proteins will subsequently activate T cells to produce immunomodulatory cytokines and will directly influence the cytokines, chemokines, and surface antigens produced by the exposed antigen presenting cells. The present invention relates to peptides and peptide analogs of heat shock proteins capable of interacting directly with dendritic cells. The present invention further relates to pharmaceutical compositions that include dendritic cells exposed to such peptides and analogs, useful for prevention or treatment of either inflammatory disorders and autoimmune diseases or malignancies, viral infections and allergy.
Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Type:
Grant
Filed:
February 13, 2001
Date of Patent:
August 11, 2009
Assignee:
The Regents of the University of California
Abstract: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
Abstract: The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
Type:
Grant
Filed:
May 15, 2006
Date of Patent:
August 4, 2009
Inventors:
Magnus Von Knebel Doeberitz, Michael Linnebacher, Wolfgang Rudy
Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.
Type:
Grant
Filed:
July 14, 2006
Date of Patent:
July 14, 2009
Assignee:
Sangamo Bioschiences, Inc.
Inventors:
Edward Rebar, Andrew Jamieson, Qiang Liu, Pei-Qi Liu, Alan Wolffe, Stephen P. Eisenberg, Eric Jarvis
Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.
Abstract: An isolated acid having the sequence of a) SEQ ID NO: 1; b) the sequence of SEQ ID NO: 2; c) the sequence of SEQ ID NO: 3; d) a sequence complementary to any of a), b), or c); or e) a sequence of at least 10 contiguous nucleotides specific for any of a)-d). The invention relates to the identification and characterization of a hitherto unidentified human gene, hGC-1. The protein encoded by hGC-1 appears to be a member of the olfactomedin-related proteins. The invention relates generally to the gene (hGC-1), nucleic acids, cDNA, vectors, polypeptides, protein, antibodies, cells, transgenic animal, and other compositions related to hGC-1. Additionally, primers are provided for identifying hGC-1. The invention further relates to methods of using these compositions, such as diagnosis and treatment of various cancers, and kits comprising these compositions.
Type:
Grant
Filed:
December 9, 2002
Date of Patent:
July 7, 2009
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Griffin P. Rodgers, Wen-li Liu, Jiachang Zhang
Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
Type:
Grant
Filed:
November 12, 2004
Date of Patent:
June 23, 2009
Assignee:
Board of Regents, The University of Texas System
Inventors:
Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
Abstract: The present invention provides that ERR? is a breast cancer biomarker of clinical course and treatment sensitivity and, itself, a target for breast cancer treatment. A high ERR? level in breast cancer indicates poor prognosis. Analyzing ERR? expression level along with the status of ER? and ErbB2 can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by modulating ERR? activity.
Type:
Grant
Filed:
September 5, 2002
Date of Patent:
June 2, 2009
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Janet E. Mertz, Stephen D. Johnston, Richard J. Kraus, Eric A. Ariazi
Abstract: Methods for the diagnosis of cancer by determining the neoplastic status of a cell by probing the cell plasma membrane for the presence of nucleolin are provided, as are kits to carry out such tests.
Type:
Grant
Filed:
April 8, 2002
Date of Patent:
June 2, 2009
Assignee:
University of Louisville Research Foundation, Inc
Inventors:
Donald M. Miller, Paula J. Bates, John O. Trent, Xiaohua Xu
Abstract: The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.
Type:
Grant
Filed:
December 5, 2005
Date of Patent:
May 26, 2009
Assignee:
The Board of Trustees of the University of Arkansas
Inventors:
Lowell J. Underwood, Timothy J. O'Brien
Abstract: ?-netrin nucleic acid molecules and polypeptides are provided. Methods of using the ?-netrin nucleic acid molecules and polypeptides are also provided.
Type:
Grant
Filed:
April 26, 2004
Date of Patent:
May 12, 2009
Assignee:
The General Hospital Corporation
Inventors:
Pamela Olson, Dale Hunter, William Brunken, Manuel Koch, Robert Burgeson
Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.
Abstract: The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.
Type:
Grant
Filed:
February 20, 2004
Date of Patent:
April 28, 2009
Assignee:
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
Inventors:
Axel Ullrich, Andreas Gschwind, Stefan Hart